A phase I study of ADXS-504, a cancer type specific immunotherapy, for patients with biochemically recurrent prostate cancer. Background: The therapeutic benefit of pelvic lymph node dissection (PLND) ...
Impact of PSMA-targeted imaging with 18F-DCFPyL-PET/CT on clinical management of patients (pts) with biochemically recurrent (BCR) prostate cancer (PCa): Results from a phase III, prospective, ...
Results from the PHENIX-I trial support skipping pelvic lymphadenectomy in women with early cervical cancer who have a negative sentinel lymph node biopsy. Omitting pelvic lymphadenectomy in these ...
The role of pelvic lymph node dissection (PLND) in patients with localized prostate cancer remains controversial. Although guidelines are increasingly recommending extended PLND alongside radical ...
"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...
Preoperative (left; top and bottom) and postoperative PSMA-PET/CT images (right; top and bottom) demonstrate the successful removal of two positive pelvic lymph nodes in the radioguided surgical ...
68Ga-PSMA-11 PET scans have a 40% sensitivity for detecting pelvic nodal metastasis in men with intermediate- or high-risk prostate cancer, data show. Pelvic lymph node dissection still may be ...
Oncologic and complication rates generally favored the minimally invasive approach to inguinal lymph node dissection in penile cancer surgery. Minimally invasive approaches to inguinal lymph node ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results